| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antineoplastic Combined Chemotherapy Protocols | 13 | 2022 | 468 | 2.870 |
Why?
|
| Head and Neck Neoplasms | 21 | 2022 | 561 | 2.760 |
Why?
|
| Secretagogins | 7 | 2022 | 7 | 2.540 |
Why?
|
| Carcinoma, Squamous Cell | 20 | 2021 | 629 | 2.380 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 3 | 2020 | 15 | 1.610 |
Why?
|
| Carboplatin | 9 | 2022 | 59 | 1.380 |
Why?
|
| Esophageal Neoplasms | 4 | 2022 | 150 | 1.310 |
Why?
|
| Radiation Injuries | 6 | 2018 | 97 | 1.240 |
Why?
|
| Testicular Neoplasms | 4 | 2022 | 27 | 1.230 |
Why?
|
| Lung Neoplasms | 8 | 2018 | 1173 | 1.220 |
Why?
|
| Seminoma | 4 | 2022 | 6 | 1.220 |
Why?
|
| Insulin-Secreting Cells | 4 | 2022 | 41 | 1.180 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2019 | 235 | 0.980 |
Why?
|
| Neoplasm Recurrence, Local | 6 | 2022 | 446 | 0.940 |
Why?
|
| Oculomotor Muscles | 2 | 2014 | 54 | 0.930 |
Why?
|
| Male | 65 | 2022 | 37321 | 0.920 |
Why?
|
| Humans | 95 | 2022 | 68618 | 0.900 |
Why?
|
| Survival Rate | 17 | 2021 | 1056 | 0.900 |
Why?
|
| Combined Modality Therapy | 18 | 2021 | 951 | 0.890 |
Why?
|
| Middle Aged | 51 | 2022 | 21147 | 0.870 |
Why?
|
| Strabismus | 2 | 2014 | 37 | 0.850 |
Why?
|
| Neoplasm Staging | 16 | 2022 | 800 | 0.830 |
Why?
|
| Pregnant Women | 1 | 2022 | 50 | 0.820 |
Why?
|
| Radiotherapy, Adjuvant | 10 | 2022 | 125 | 0.810 |
Why?
|
| Cisplatin | 9 | 2019 | 192 | 0.810 |
Why?
|
| Aged | 39 | 2022 | 14862 | 0.770 |
Why?
|
| Bone Marrow | 2 | 2019 | 168 | 0.760 |
Why?
|
| Thrombocytopenia | 2 | 2019 | 122 | 0.750 |
Why?
|
| Radiopharmaceuticals | 4 | 2022 | 114 | 0.730 |
Why?
|
| Retrospective Studies | 28 | 2021 | 7277 | 0.730 |
Why?
|
| EF Hand Motifs | 2 | 2022 | 6 | 0.720 |
Why?
|
| Female | 55 | 2022 | 38074 | 0.710 |
Why?
|
| Budd-Chiari Syndrome | 1 | 2020 | 7 | 0.710 |
Why?
|
| Treatment Outcome | 25 | 2020 | 7029 | 0.700 |
Why?
|
| Esophageal and Gastric Varices | 1 | 2020 | 47 | 0.670 |
Why?
|
| Tomography, Optical Coherence | 3 | 2020 | 88 | 0.660 |
Why?
|
| Adenocarcinoma | 4 | 2022 | 475 | 0.630 |
Why?
|
| Radium | 1 | 2018 | 12 | 0.630 |
Why?
|
| Formative Feedback | 1 | 2018 | 8 | 0.620 |
Why?
|
| Adult | 32 | 2022 | 21403 | 0.620 |
Why?
|
| Regeneration | 1 | 2019 | 105 | 0.610 |
Why?
|
| Retinal Ganglion Cells | 2 | 2018 | 72 | 0.600 |
Why?
|
| Bone Neoplasms | 1 | 2018 | 100 | 0.600 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2020 | 185 | 0.600 |
Why?
|
| Anemia | 1 | 2018 | 104 | 0.590 |
Why?
|
| Research Personnel | 1 | 2018 | 83 | 0.580 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2019 | 148 | 0.570 |
Why?
|
| Anticoagulants | 1 | 2020 | 356 | 0.570 |
Why?
|
| Pancreatic Neoplasms | 2 | 2013 | 332 | 0.560 |
Why?
|
| Insulin | 2 | 2022 | 619 | 0.560 |
Why?
|
| Neurofibroma | 1 | 2016 | 11 | 0.550 |
Why?
|
| Vertebral Artery | 1 | 2016 | 22 | 0.550 |
Why?
|
| Calcium | 5 | 2022 | 929 | 0.550 |
Why?
|
| Radiation Dosage | 2 | 2018 | 419 | 0.540 |
Why?
|
| Nerve Sheath Neoplasms | 1 | 2016 | 33 | 0.530 |
Why?
|
| Nerve Fibers | 2 | 2018 | 77 | 0.510 |
Why?
|
| Prognosis | 14 | 2021 | 2093 | 0.510 |
Why?
|
| Biochemistry | 1 | 2015 | 12 | 0.500 |
Why?
|
| Communication | 1 | 2018 | 329 | 0.500 |
Why?
|
| Antineoplastic Agents | 5 | 2020 | 1070 | 0.490 |
Why?
|
| Escherichia coli | 3 | 2017 | 368 | 0.490 |
Why?
|
| Radiotherapy Dosage | 4 | 2014 | 125 | 0.490 |
Why?
|
| Cysticercosis | 1 | 2014 | 1 | 0.480 |
Why?
|
| Eye Infections, Parasitic | 1 | 2014 | 1 | 0.480 |
Why?
|
| Taenia solium | 1 | 2014 | 1 | 0.480 |
Why?
|
| Follow-Up Studies | 13 | 2022 | 3259 | 0.480 |
Why?
|
| Esophageal Stenosis | 3 | 2012 | 36 | 0.480 |
Why?
|
| Blepharoptosis | 1 | 2014 | 7 | 0.480 |
Why?
|
| Esophagectomy | 1 | 2014 | 26 | 0.480 |
Why?
|
| Salvage Therapy | 2 | 2020 | 82 | 0.470 |
Why?
|
| Ophthalmologic Surgical Procedures | 1 | 2014 | 32 | 0.470 |
Why?
|
| Mutation | 1 | 2019 | 1213 | 0.470 |
Why?
|
| Proportional Hazards Models | 8 | 2020 | 792 | 0.470 |
Why?
|
| Nepal | 9 | 2020 | 12 | 0.460 |
Why?
|
| Glaucoma | 1 | 2014 | 50 | 0.460 |
Why?
|
| Pulmonary Blastoma | 1 | 2013 | 7 | 0.460 |
Why?
|
| Tertiary Care Centers | 4 | 2019 | 67 | 0.450 |
Why?
|
| Radiotherapy | 2 | 2010 | 86 | 0.450 |
Why?
|
| Laryngectomy | 2 | 2017 | 30 | 0.450 |
Why?
|
| Small Cell Lung Carcinoma | 2 | 2010 | 17 | 0.440 |
Why?
|
| Glaucoma, Angle-Closure | 1 | 2013 | 3 | 0.440 |
Why?
|
| Aged, 80 and over | 15 | 2022 | 4848 | 0.430 |
Why?
|
| Diabetes Mellitus | 1 | 2019 | 694 | 0.430 |
Why?
|
| Survival Analysis | 4 | 2019 | 714 | 0.420 |
Why?
|
| Disease-Free Survival | 6 | 2019 | 349 | 0.420 |
Why?
|
| Papilloma, Inverted | 1 | 2012 | 8 | 0.420 |
Why?
|
| Young Adult | 11 | 2021 | 5717 | 0.420 |
Why?
|
| Skull Neoplasms | 1 | 2012 | 23 | 0.410 |
Why?
|
| Esophagitis | 2 | 2010 | 45 | 0.410 |
Why?
|
| Prostatic Neoplasms | 1 | 2018 | 778 | 0.410 |
Why?
|
| Patient Satisfaction | 2 | 2014 | 378 | 0.410 |
Why?
|
| Temporal Bone | 1 | 2012 | 53 | 0.410 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2012 | 46 | 0.410 |
Why?
|
| Duane Retraction Syndrome | 1 | 2011 | 5 | 0.400 |
Why?
|
| Radiotherapy, Intensity-Modulated | 2 | 2014 | 30 | 0.400 |
Why?
|
| Vision, Binocular | 1 | 2011 | 30 | 0.390 |
Why?
|
| Amblyopia | 1 | 2011 | 43 | 0.380 |
Why?
|
| Waardenburg Syndrome | 1 | 2010 | 5 | 0.370 |
Why?
|
| Hypopigmentation | 1 | 2010 | 12 | 0.370 |
Why?
|
| Positron Emission Tomography Computed Tomography | 3 | 2022 | 38 | 0.370 |
Why?
|
| STAT3 Transcription Factor | 3 | 2015 | 86 | 0.370 |
Why?
|
| Carcinoma, Small Cell | 1 | 2010 | 53 | 0.370 |
Why?
|
| Fluorodeoxyglucose F18 | 3 | 2022 | 81 | 0.350 |
Why?
|
| Oropharyngeal Neoplasms | 4 | 2015 | 94 | 0.350 |
Why?
|
| Automobile Driving | 2 | 2008 | 88 | 0.350 |
Why?
|
| Deafness | 1 | 2010 | 64 | 0.350 |
Why?
|
| Xerostomia | 3 | 2015 | 24 | 0.340 |
Why?
|
| Optic Neuritis | 3 | 2019 | 26 | 0.340 |
Why?
|
| Risk Factors | 13 | 2021 | 5731 | 0.330 |
Why?
|
| Chemoradiotherapy, Adjuvant | 3 | 2021 | 33 | 0.330 |
Why?
|
| Percutaneous Coronary Intervention | 2 | 2021 | 137 | 0.330 |
Why?
|
| Adolescent | 10 | 2020 | 8912 | 0.330 |
Why?
|
| Schizophrenia | 1 | 2010 | 206 | 0.320 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2018 | 536 | 0.310 |
Why?
|
| Cornea | 3 | 2020 | 76 | 0.300 |
Why?
|
| Otorhinolaryngologic Neoplasms | 1 | 2007 | 7 | 0.300 |
Why?
|
| Thyroid Neoplasms | 2 | 2007 | 68 | 0.300 |
Why?
|
| Circular Dichroism | 2 | 2019 | 99 | 0.280 |
Why?
|
| Pelvic Neoplasms | 1 | 2006 | 13 | 0.270 |
Why?
|
| Myxoma | 1 | 2006 | 17 | 0.270 |
Why?
|
| Time Factors | 9 | 2020 | 4655 | 0.270 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 3 | 2018 | 300 | 0.270 |
Why?
|
| Child | 9 | 2020 | 6405 | 0.270 |
Why?
|
| Tomography, X-Ray Computed | 6 | 2022 | 2324 | 0.270 |
Why?
|
| Animals | 12 | 2022 | 20881 | 0.260 |
Why?
|
| Radiosurgery | 2 | 2018 | 66 | 0.260 |
Why?
|
| Guideline Adherence | 2 | 2018 | 287 | 0.260 |
Why?
|
| Retreatment | 2 | 2019 | 59 | 0.250 |
Why?
|
| Neoplasm Metastasis | 2 | 2019 | 306 | 0.250 |
Why?
|
| Protein Aggregation, Pathological | 2 | 2022 | 13 | 0.250 |
Why?
|
| Oxidative Stress | 2 | 2022 | 718 | 0.250 |
Why?
|
| Adenocarcinoma, Papillary | 1 | 2005 | 12 | 0.250 |
Why?
|
| Salivary Gland Neoplasms | 2 | 2021 | 40 | 0.250 |
Why?
|
| Neutropenia | 2 | 2019 | 72 | 0.250 |
Why?
|
| Visual Acuity | 4 | 2021 | 236 | 0.250 |
Why?
|
| Thyroidectomy | 1 | 2005 | 31 | 0.250 |
Why?
|
| Adenocarcinoma, Follicular | 1 | 2005 | 13 | 0.250 |
Why?
|
| von Willebrand Factor | 2 | 2021 | 47 | 0.230 |
Why?
|
| Breast Neoplasms | 2 | 2010 | 1536 | 0.230 |
Why?
|
| alpha-Synuclein | 2 | 2022 | 28 | 0.220 |
Why?
|
| Paclitaxel | 3 | 2022 | 140 | 0.220 |
Why?
|
| Registries | 4 | 2021 | 733 | 0.220 |
Why?
|
| Laryngeal Neoplasms | 2 | 2017 | 47 | 0.220 |
Why?
|
| Nitric Oxide | 2 | 2015 | 382 | 0.210 |
Why?
|
| Proteostasis Deficiencies | 1 | 2022 | 2 | 0.210 |
Why?
|
| Heat-Shock Response | 1 | 2022 | 7 | 0.210 |
Why?
|
| Nuts | 1 | 2022 | 2 | 0.210 |
Why?
|
| Starch | 1 | 2022 | 18 | 0.210 |
Why?
|
| Neck | 1 | 2022 | 62 | 0.210 |
Why?
|
| Radiotherapy, Conformal | 3 | 2014 | 24 | 0.200 |
Why?
|
| Trastuzumab | 1 | 2022 | 17 | 0.200 |
Why?
|
| Plasma Exchange | 1 | 2021 | 18 | 0.200 |
Why?
|
| Hepatitis, Alcoholic | 1 | 2021 | 5 | 0.200 |
Why?
|
| Molecular Chaperones | 1 | 2022 | 81 | 0.200 |
Why?
|
| Carcinoma, Adenoid Cystic | 1 | 2021 | 12 | 0.200 |
Why?
|
| Optic Nerve | 2 | 2021 | 55 | 0.200 |
Why?
|
| Carcinoma, Acinar Cell | 1 | 2021 | 14 | 0.200 |
Why?
|
| Recurrence | 4 | 2020 | 948 | 0.200 |
Why?
|
| Adipocytes | 1 | 2021 | 88 | 0.190 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2022 | 138 | 0.190 |
Why?
|
| Cell Line | 3 | 2022 | 1752 | 0.190 |
Why?
|
| Fatty Liver | 1 | 2021 | 97 | 0.190 |
Why?
|
| Optic Atrophy | 1 | 2021 | 2 | 0.190 |
Why?
|
| Doxorubicin | 2 | 2013 | 231 | 0.190 |
Why?
|
| Receptor, ErbB-2 | 1 | 2022 | 129 | 0.190 |
Why?
|
| Visual Fields | 2 | 2021 | 41 | 0.190 |
Why?
|
| End Stage Liver Disease | 1 | 2021 | 60 | 0.190 |
Why?
|
| Camptothecin | 2 | 2010 | 39 | 0.180 |
Why?
|
| Mice | 6 | 2019 | 8474 | 0.180 |
Why?
|
| Evoked Potentials, Visual | 2 | 2018 | 18 | 0.180 |
Why?
|
| Panuveitis | 1 | 2020 | 1 | 0.180 |
Why?
|
| Adipose Tissue | 1 | 2021 | 221 | 0.180 |
Why?
|
| Stem Cell Transplantation | 1 | 2020 | 58 | 0.180 |
Why?
|
| Moths | 1 | 2020 | 14 | 0.180 |
Why?
|
| Energy Intake | 1 | 2021 | 123 | 0.180 |
Why?
|
| Rodenticides | 1 | 2020 | 1 | 0.180 |
Why?
|
| von Willebrand Diseases | 1 | 2020 | 11 | 0.180 |
Why?
|
| Prevalence | 3 | 2014 | 1619 | 0.180 |
Why?
|
| Neoplasms, Second Primary | 1 | 2020 | 62 | 0.180 |
Why?
|
| ST Elevation Myocardial Infarction | 1 | 2020 | 10 | 0.180 |
Why?
|
| Reference Values | 2 | 2014 | 579 | 0.180 |
Why?
|
| Coronary Thrombosis | 1 | 2020 | 45 | 0.170 |
Why?
|
| Mouth Neoplasms | 2 | 2017 | 206 | 0.170 |
Why?
|
| Pregnancy | 2 | 2022 | 2334 | 0.170 |
Why?
|
| Etoposide | 2 | 2010 | 64 | 0.170 |
Why?
|
| Cross-Sectional Studies | 6 | 2018 | 2279 | 0.170 |
Why?
|
| Liver Failure, Acute | 1 | 2020 | 49 | 0.170 |
Why?
|
| Papilledema | 1 | 2019 | 21 | 0.170 |
Why?
|
| Energy Metabolism | 1 | 2021 | 222 | 0.170 |
Why?
|
| Sex Distribution | 3 | 2019 | 274 | 0.170 |
Why?
|
| Age Distribution | 3 | 2019 | 320 | 0.160 |
Why?
|
| Biophysical Phenomena | 1 | 2019 | 25 | 0.160 |
Why?
|
| NIH 3T3 Cells | 1 | 2019 | 65 | 0.160 |
Why?
|
| Multimodal Imaging | 2 | 2016 | 62 | 0.160 |
Why?
|
| Hep G2 Cells | 1 | 2019 | 68 | 0.160 |
Why?
|
| Quality Control | 1 | 2019 | 81 | 0.160 |
Why?
|
| Pregnancy Complications | 1 | 2021 | 286 | 0.160 |
Why?
|
| Positron-Emission Tomography | 2 | 2022 | 160 | 0.160 |
Why?
|
| England | 1 | 2018 | 64 | 0.160 |
Why?
|
| Disease Susceptibility | 1 | 2019 | 179 | 0.160 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2020 | 131 | 0.160 |
Why?
|
| Protein Structure, Secondary | 2 | 2017 | 136 | 0.160 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2020 | 171 | 0.160 |
Why?
|
| Travel | 1 | 2018 | 38 | 0.150 |
Why?
|
| Child, Preschool | 3 | 2017 | 3187 | 0.150 |
Why?
|
| Protein Multimerization | 2 | 2017 | 71 | 0.150 |
Why?
|
| Multivariate Analysis | 3 | 2017 | 1046 | 0.150 |
Why?
|
| Health Services | 1 | 2018 | 87 | 0.150 |
Why?
|
| Congresses as Topic | 1 | 2018 | 85 | 0.150 |
Why?
|
| Cohort Studies | 3 | 2014 | 2358 | 0.150 |
Why?
|
| Palliative Care | 2 | 2012 | 271 | 0.140 |
Why?
|
| Color Vision | 1 | 2017 | 2 | 0.140 |
Why?
|
| Chi-Square Distribution | 1 | 2018 | 546 | 0.140 |
Why?
|
| Chemotherapy, Adjuvant | 4 | 2022 | 129 | 0.140 |
Why?
|
| Tranexamic Acid | 1 | 2017 | 37 | 0.140 |
Why?
|
| Postoperative Hemorrhage | 1 | 2017 | 69 | 0.140 |
Why?
|
| Antifibrinolytic Agents | 1 | 2017 | 52 | 0.140 |
Why?
|
| Blood Loss, Surgical | 1 | 2017 | 79 | 0.140 |
Why?
|
| Eye Infections, Fungal | 1 | 2016 | 7 | 0.140 |
Why?
|
| Cysteine | 1 | 2017 | 112 | 0.140 |
Why?
|
| Keratitis | 1 | 2016 | 20 | 0.140 |
Why?
|
| Otorhinolaryngologic Surgical Procedures | 1 | 2017 | 62 | 0.140 |
Why?
|
| Quadriplegia | 1 | 2016 | 29 | 0.140 |
Why?
|
| Iatrogenic Disease | 1 | 2016 | 36 | 0.140 |
Why?
|
| Spinal Cord Compression | 1 | 2016 | 23 | 0.140 |
Why?
|
| Odds Ratio | 1 | 2018 | 880 | 0.130 |
Why?
|
| Neck Dissection | 3 | 2021 | 55 | 0.130 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2016 | 2223 | 0.130 |
Why?
|
| Calcium-Binding Proteins | 1 | 2016 | 114 | 0.130 |
Why?
|
| Aneurysm, False | 1 | 2016 | 60 | 0.130 |
Why?
|
| Endovascular Procedures | 1 | 2020 | 366 | 0.130 |
Why?
|
| Conjunctivitis, Allergic | 1 | 2015 | 2 | 0.130 |
Why?
|
| Corneal Topography | 1 | 2015 | 2 | 0.130 |
Why?
|
| Cervical Vertebrae | 1 | 2016 | 86 | 0.130 |
Why?
|
| Intraoperative Complications | 1 | 2016 | 129 | 0.130 |
Why?
|
| Keratoconus | 1 | 2015 | 4 | 0.130 |
Why?
|
| Predictive Value of Tests | 4 | 2021 | 1465 | 0.130 |
Why?
|
| Practice Guidelines as Topic | 2 | 2017 | 772 | 0.130 |
Why?
|
| Protein Refolding | 1 | 2015 | 4 | 0.130 |
Why?
|
| Hyperbaric Oxygenation | 1 | 2015 | 11 | 0.130 |
Why?
|
| Neuronal Calcium-Sensor Proteins | 1 | 2015 | 1 | 0.130 |
Why?
|
| Myristic Acids | 1 | 2015 | 3 | 0.130 |
Why?
|
| Hydrodynamics | 1 | 2015 | 15 | 0.130 |
Why?
|
| Calorimetry | 1 | 2015 | 21 | 0.130 |
Why?
|
| Nitric Oxide Donors | 1 | 2015 | 54 | 0.130 |
Why?
|
| Risk Assessment | 6 | 2020 | 2007 | 0.130 |
Why?
|
| Databases, Factual | 4 | 2020 | 622 | 0.120 |
Why?
|
| Tryptophan | 1 | 2015 | 65 | 0.120 |
Why?
|
| Fluorescence | 1 | 2015 | 104 | 0.120 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2015 | 272 | 0.120 |
Why?
|
| Bacterial Infections | 1 | 2016 | 163 | 0.120 |
Why?
|
| Incidence | 4 | 2017 | 1603 | 0.120 |
Why?
|
| Retinal Hemorrhage | 1 | 2014 | 7 | 0.120 |
Why?
|
| Rats | 2 | 2022 | 5300 | 0.120 |
Why?
|
| Magnesium | 1 | 2015 | 110 | 0.120 |
Why?
|
| Thermodynamics | 1 | 2015 | 162 | 0.120 |
Why?
|
| Age Factors | 2 | 2018 | 1864 | 0.120 |
Why?
|
| Carcinoma | 2 | 2007 | 215 | 0.120 |
Why?
|
| Cell Cycle Proteins | 1 | 2016 | 230 | 0.120 |
Why?
|
| Deglutition | 2 | 2008 | 221 | 0.120 |
Why?
|
| S-Nitrosoglutathione | 1 | 2015 | 87 | 0.120 |
Why?
|
| Protein Structure, Tertiary | 1 | 2015 | 322 | 0.120 |
Why?
|
| Neuropeptides | 1 | 2015 | 106 | 0.120 |
Why?
|
| Logistic Models | 3 | 2017 | 1420 | 0.120 |
Why?
|
| Severity of Illness Index | 4 | 2021 | 1851 | 0.120 |
Why?
|
| United States | 5 | 2021 | 7367 | 0.120 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2014 | 70 | 0.120 |
Why?
|
| Coronary Artery Disease | 1 | 2020 | 696 | 0.110 |
Why?
|
| Liver Transplantation | 1 | 2017 | 400 | 0.110 |
Why?
|
| SEER Program | 1 | 2014 | 153 | 0.110 |
Why?
|
| Obesity | 1 | 2021 | 1076 | 0.110 |
Why?
|
| Vincristine | 1 | 2013 | 44 | 0.110 |
Why?
|
| Quality of Life | 3 | 2019 | 1515 | 0.110 |
Why?
|
| Salivary Glands | 1 | 2013 | 52 | 0.110 |
Why?
|
| Gene Expression | 1 | 2016 | 770 | 0.110 |
Why?
|
| Prospective Studies | 6 | 2020 | 3705 | 0.110 |
Why?
|
| Neoplasm Proteins | 1 | 2015 | 307 | 0.110 |
Why?
|
| Ophthalmic Solutions | 1 | 2013 | 39 | 0.110 |
Why?
|
| Cyclophosphamide | 1 | 2013 | 129 | 0.110 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2014 | 91 | 0.100 |
Why?
|
| Drug Administration Schedule | 2 | 2013 | 567 | 0.100 |
Why?
|
| Submandibular Gland | 1 | 2012 | 34 | 0.100 |
Why?
|
| Methanol | 1 | 2012 | 9 | 0.100 |
Why?
|
| South Carolina | 4 | 2018 | 2752 | 0.100 |
Why?
|
| Eye Diseases | 1 | 2012 | 38 | 0.100 |
Why?
|
| Central Nervous System Diseases | 1 | 2012 | 40 | 0.100 |
Why?
|
| Osteomyelitis | 1 | 2012 | 40 | 0.100 |
Why?
|
| Eye Movements | 1 | 2011 | 44 | 0.100 |
Why?
|
| Diagnostic Imaging | 1 | 2013 | 201 | 0.100 |
Why?
|
| Deoxycytidine | 1 | 2011 | 83 | 0.100 |
Why?
|
| Biomarkers | 4 | 2021 | 1593 | 0.090 |
Why?
|
| Melanoma | 2 | 2005 | 335 | 0.090 |
Why?
|
| Refraction, Ocular | 1 | 2011 | 61 | 0.090 |
Why?
|
| Pigmentation Disorders | 1 | 2010 | 11 | 0.090 |
Why?
|
| Iris Diseases | 1 | 2010 | 8 | 0.090 |
Why?
|
| Brain Injuries | 1 | 2014 | 268 | 0.090 |
Why?
|
| Protein Binding | 3 | 2019 | 1027 | 0.090 |
Why?
|
| Sensitivity and Specificity | 3 | 2022 | 1753 | 0.090 |
Why?
|
| Oxidation-Reduction | 3 | 2017 | 567 | 0.090 |
Why?
|
| Retinopathy of Prematurity | 1 | 2009 | 34 | 0.090 |
Why?
|
| Diagnosis, Differential | 1 | 2013 | 1140 | 0.090 |
Why?
|
| Weight Gain | 1 | 2010 | 135 | 0.080 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 2009 | 113 | 0.080 |
Why?
|
| Lysophospholipids | 1 | 2010 | 209 | 0.080 |
Why?
|
| Spinal Cord | 1 | 2009 | 244 | 0.080 |
Why?
|
| Body Mass Index | 2 | 2010 | 867 | 0.080 |
Why?
|
| Area Under Curve | 1 | 2008 | 238 | 0.080 |
Why?
|
| Sphingosine | 1 | 2010 | 315 | 0.080 |
Why?
|
| Osteoradionecrosis | 1 | 2008 | 7 | 0.080 |
Why?
|
| Clinical Trials as Topic | 2 | 2010 | 848 | 0.080 |
Why?
|
| Lymphatic Metastasis | 2 | 2022 | 274 | 0.080 |
Why?
|
| Chemoradiotherapy | 2 | 2022 | 54 | 0.080 |
Why?
|
| Phosphorylation | 3 | 2015 | 1200 | 0.080 |
Why?
|
| Inflammation | 1 | 2014 | 1030 | 0.070 |
Why?
|
| Deglutition Disorders | 2 | 2012 | 297 | 0.070 |
Why?
|
| Ceramides | 1 | 2011 | 578 | 0.070 |
Why?
|
| Referral and Consultation | 2 | 2021 | 383 | 0.070 |
Why?
|
| Stents | 1 | 2012 | 657 | 0.070 |
Why?
|
| Temporal Lobe | 1 | 2008 | 125 | 0.070 |
Why?
|
| Propensity Score | 2 | 2017 | 117 | 0.070 |
Why?
|
| Acute Disease | 1 | 2008 | 658 | 0.070 |
Why?
|
| Mitomycin | 1 | 2007 | 27 | 0.070 |
Why?
|
| Reaction Time | 1 | 2007 | 170 | 0.070 |
Why?
|
| Depression | 1 | 2014 | 943 | 0.070 |
Why?
|
| Buttocks | 1 | 2006 | 16 | 0.070 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2007 | 82 | 0.070 |
Why?
|
| Protein Domains | 2 | 2017 | 74 | 0.070 |
Why?
|
| Surgical Procedures, Operative | 2 | 2004 | 124 | 0.070 |
Why?
|
| Models, Molecular | 2 | 2019 | 546 | 0.070 |
Why?
|
| Patient Selection | 1 | 2010 | 592 | 0.070 |
Why?
|
| Surveys and Questionnaires | 1 | 2014 | 2800 | 0.070 |
Why?
|
| User-Computer Interface | 1 | 2007 | 230 | 0.070 |
Why?
|
| Psychomotor Performance | 1 | 2007 | 213 | 0.070 |
Why?
|
| Survivors | 1 | 2008 | 256 | 0.060 |
Why?
|
| Attention | 1 | 2007 | 225 | 0.060 |
Why?
|
| Thyroglobulin | 1 | 2005 | 17 | 0.060 |
Why?
|
| Paranasal Sinus Neoplasms | 1 | 2005 | 23 | 0.060 |
Why?
|
| Keloid | 1 | 2004 | 10 | 0.060 |
Why?
|
| Thyroid Hormones | 1 | 2005 | 31 | 0.060 |
Why?
|
| Life Expectancy | 1 | 2005 | 51 | 0.060 |
Why?
|
| Quality of Health Care | 2 | 2018 | 322 | 0.060 |
Why?
|
| Radionuclide Imaging | 1 | 2005 | 166 | 0.060 |
Why?
|
| Recombinant Proteins | 2 | 2017 | 742 | 0.060 |
Why?
|
| Neoplasms | 1 | 2015 | 1667 | 0.060 |
Why?
|
| Sarcoma | 1 | 2005 | 70 | 0.060 |
Why?
|
| Brachytherapy | 1 | 2004 | 79 | 0.060 |
Why?
|
| Cognition | 1 | 2008 | 513 | 0.060 |
Why?
|
| Computer Simulation | 1 | 2007 | 706 | 0.060 |
Why?
|
| Pilot Projects | 1 | 2007 | 1342 | 0.060 |
Why?
|
| Functional Food | 1 | 2022 | 3 | 0.050 |
Why?
|
| Biology | 1 | 2022 | 14 | 0.050 |
Why?
|
| Nutritive Value | 1 | 2022 | 22 | 0.050 |
Why?
|
| Orchiectomy | 1 | 2022 | 25 | 0.050 |
Why?
|
| Protein Folding | 1 | 2022 | 82 | 0.050 |
Why?
|
| Mononuclear Phagocyte System | 1 | 2021 | 8 | 0.050 |
Why?
|
| Ferritins | 1 | 2021 | 49 | 0.050 |
Why?
|
| Cell Survival | 2 | 2015 | 901 | 0.050 |
Why?
|
| Endocytosis | 1 | 2022 | 113 | 0.050 |
Why?
|
| HEK293 Cells | 1 | 2022 | 326 | 0.050 |
Why?
|
| Margins of Excision | 1 | 2021 | 15 | 0.050 |
Why?
|
| Cell Line, Tumor | 2 | 2017 | 1851 | 0.050 |
Why?
|
| Lymph Nodes | 1 | 2022 | 258 | 0.050 |
Why?
|
| Atrophy | 1 | 2021 | 112 | 0.050 |
Why?
|
| Gastrostomy | 2 | 2014 | 110 | 0.050 |
Why?
|
| Disease Progression | 2 | 2019 | 1038 | 0.050 |
Why?
|
| United Kingdom | 1 | 2020 | 152 | 0.040 |
Why?
|
| Victoria | 1 | 2020 | 8 | 0.040 |
Why?
|
| Australia | 1 | 2021 | 235 | 0.040 |
Why?
|
| Multiple Organ Failure | 1 | 2020 | 36 | 0.040 |
Why?
|
| Seasons | 1 | 2020 | 129 | 0.040 |
Why?
|
| Proteomics | 1 | 2022 | 246 | 0.040 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2019 | 57 | 0.040 |
Why?
|
| London | 1 | 2019 | 12 | 0.040 |
Why?
|
| Contrast Sensitivity | 1 | 2019 | 28 | 0.040 |
Why?
|
| Clinical Protocols | 1 | 2020 | 172 | 0.040 |
Why?
|
| Pseudotumor Cerebri | 1 | 2019 | 43 | 0.040 |
Why?
|
| Vision Disorders | 1 | 2019 | 94 | 0.040 |
Why?
|
| Endothelial Cells | 1 | 2021 | 384 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2019 | 109 | 0.040 |
Why?
|
| Optic Disk | 1 | 2018 | 37 | 0.040 |
Why?
|
| Stroke Volume | 1 | 2021 | 586 | 0.040 |
Why?
|
| Papillomavirus Infections | 1 | 2020 | 194 | 0.040 |
Why?
|
| Hospital Mortality | 1 | 2020 | 384 | 0.040 |
Why?
|
| Life Style | 3 | 2005 | 338 | 0.040 |
Why?
|
| Reproducibility of Results | 2 | 2014 | 2077 | 0.040 |
Why?
|
| Ventricular Function, Left | 1 | 2021 | 481 | 0.040 |
Why?
|
| Ophthalmoscopy | 1 | 2017 | 13 | 0.040 |
Why?
|
| Dithiothreitol | 1 | 2017 | 17 | 0.040 |
Why?
|
| Erythrocyte Transfusion | 1 | 2017 | 72 | 0.040 |
Why?
|
| Thromboembolism | 1 | 2017 | 91 | 0.040 |
Why?
|
| Cytosol | 1 | 2017 | 123 | 0.030 |
Why?
|
| Lymph Node Excision | 1 | 2017 | 91 | 0.030 |
Why?
|
| Diet | 3 | 2005 | 514 | 0.030 |
Why?
|
| Aspergillosis | 1 | 2016 | 20 | 0.030 |
Why?
|
| Cloning, Molecular | 1 | 2017 | 357 | 0.030 |
Why?
|
| Microscopy | 1 | 2016 | 64 | 0.030 |
Why?
|
| Educational Status | 1 | 2017 | 273 | 0.030 |
Why?
|
| Delivery of Health Care | 1 | 2020 | 445 | 0.030 |
Why?
|
| Janus Kinase 2 | 1 | 2015 | 40 | 0.030 |
Why?
|
| Endoplasmic Reticulum | 1 | 2017 | 148 | 0.030 |
Why?
|
| Cell Nucleus | 1 | 2017 | 305 | 0.030 |
Why?
|
| Insurance, Health | 1 | 2017 | 201 | 0.030 |
Why?
|
| Gamma Rays | 1 | 2015 | 64 | 0.030 |
Why?
|
| Binding Sites | 1 | 2017 | 631 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2015 | 132 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2017 | 281 | 0.030 |
Why?
|
| Amino Acid Motifs | 1 | 2015 | 77 | 0.030 |
Why?
|
| Staphylococcal Infections | 1 | 2016 | 156 | 0.030 |
Why?
|
| Mice, Nude | 1 | 2015 | 294 | 0.030 |
Why?
|
| Medicare | 1 | 2017 | 319 | 0.030 |
Why?
|
| Medicaid | 1 | 2017 | 302 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2015 | 304 | 0.030 |
Why?
|
| Patient Readmission | 1 | 2017 | 267 | 0.030 |
Why?
|
| ROC Curve | 1 | 2015 | 392 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 2015 | 330 | 0.030 |
Why?
|
| Disease | 1 | 2014 | 41 | 0.030 |
Why?
|
| Early Diagnosis | 1 | 2014 | 122 | 0.030 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2014 | 36 | 0.030 |
Why?
|
| Postoperative Period | 1 | 2014 | 238 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2021 | 2550 | 0.030 |
Why?
|
| Length of Stay | 1 | 2017 | 780 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2015 | 649 | 0.030 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2013 | 12 | 0.030 |
Why?
|
| NF-kappa B | 1 | 2015 | 432 | 0.030 |
Why?
|
| Remission Induction | 1 | 2013 | 111 | 0.030 |
Why?
|
| Exanthema | 1 | 2013 | 30 | 0.030 |
Why?
|
| Amino Acid Sequence | 1 | 2015 | 1083 | 0.030 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2013 | 144 | 0.030 |
Why?
|
| Quinazolines | 1 | 2013 | 70 | 0.030 |
Why?
|
| Comorbidity | 1 | 2017 | 1426 | 0.030 |
Why?
|
| Molecular Sequence Data | 1 | 2015 | 1447 | 0.030 |
Why?
|
| Pharyngeal Neoplasms | 1 | 2012 | 8 | 0.030 |
Why?
|
| Cephalosporins | 1 | 2012 | 59 | 0.030 |
Why?
|
| Vancomycin | 1 | 2012 | 60 | 0.020 |
Why?
|
| Electroretinography | 1 | 2012 | 122 | 0.020 |
Why?
|
| Weight Loss | 1 | 2014 | 319 | 0.020 |
Why?
|
| Methylprednisolone | 1 | 2012 | 99 | 0.020 |
Why?
|
| ErbB Receptors | 1 | 2013 | 239 | 0.020 |
Why?
|
| Solvents | 1 | 2012 | 109 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2012 | 334 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2015 | 756 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2017 | 1293 | 0.020 |
Why?
|
| Renal Dialysis | 1 | 2012 | 174 | 0.020 |
Why?
|
| Radiography | 1 | 2012 | 572 | 0.020 |
Why?
|
| Metabolomics | 1 | 2010 | 28 | 0.020 |
Why?
|
| Infant | 1 | 2017 | 2891 | 0.020 |
Why?
|
| Neoadjuvant Therapy | 1 | 2010 | 104 | 0.020 |
Why?
|
| Blood Volume | 1 | 2009 | 47 | 0.020 |
Why?
|
| Capillary Permeability | 1 | 2009 | 69 | 0.020 |
Why?
|
| Regional Blood Flow | 1 | 2009 | 168 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2014 | 1174 | 0.020 |
Why?
|
| Pain | 1 | 2013 | 472 | 0.020 |
Why?
|
| Blood Flow Velocity | 1 | 2009 | 172 | 0.020 |
Why?
|
| Neuroprotective Agents | 1 | 2012 | 317 | 0.020 |
Why?
|
| Birth Weight | 1 | 2009 | 186 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2010 | 447 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2014 | 2673 | 0.020 |
Why?
|
| Gestational Age | 1 | 2009 | 389 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 2008 | 219 | 0.020 |
Why?
|
| Enteral Nutrition | 1 | 2008 | 157 | 0.020 |
Why?
|
| Dilatation | 1 | 2007 | 58 | 0.020 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2006 | 84 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2015 | 2689 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2012 | 1026 | 0.020 |
Why?
|
| Mucous Membrane | 1 | 2005 | 66 | 0.020 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2005 | 53 | 0.020 |
Why?
|
| Cancer Vaccines | 1 | 2005 | 61 | 0.020 |
Why?
|
| Interleukin-2 | 1 | 2005 | 133 | 0.010 |
Why?
|
| Treatment Failure | 1 | 2004 | 216 | 0.010 |
Why?
|
| Biopsy | 1 | 2006 | 540 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2009 | 2455 | 0.010 |
Why?
|
| Oral Surgical Procedures | 1 | 2003 | 15 | 0.010 |
Why?
|
| Microsurgery | 1 | 2003 | 46 | 0.010 |
Why?
|